{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:40Z","timestamp":1794255880263,"version":"4.9.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03731-z","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:49:26Z","timestamp":1787370566000},"page":"5232-5253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabry Disease: An Updated Perspective and Review of Treatment and Therapies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-8078","authenticated-orcid":false,"given":"Dawn A.","family":"Laney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelena M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddarth V.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma P.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"3731_CR1","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, et al. Alpha-galactosidase\u00a0A 364 deficiency: Fabry disease. In: Crba S, Sly WS, Valle D, editors, et al. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw Hill; 2001. p. 3733\u201374.","edition":"8th edn"},{"issue":"10","key":"3731_CR2","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","volume":"3","author":"CM Eng","year":"1994","unstructured":"Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase\u00a0A gene. Hum Mol Genet. 1994;3(10):1795\u20139. https:\/\/doi.org\/10.1093\/hmg\/3.10.1795.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"3731_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3731_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymgme.2022.10.005","volume":"137","author":"C T\u00f8ndel","year":"2022","unstructured":"T\u00f8ndel C, Thurberg BL, DasMahapatra P, et al. Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. Mol Genet Metab. 2022;137(4):328\u201341. https:\/\/doi.org\/10.1016\/j.ymgme.2022.10.005.","journal-title":"Mol Genet Metab"},{"issue":"1-2","key":"3731_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.010.","journal-title":"Mol Genet Metab"},{"issue":"11","key":"3731_CR6","doi-asserted-by":"publisher","first-page":"1420067","DOI":"10.3389\/fcvm.2024.1420067","volume":"12","author":"H Kurdi","year":"2024","unstructured":"Kurdi H, Lavalle L, Moon JCC, Hughes D. Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications. Front Cardiovasc Med. 2024;12(11):1420067. https:\/\/doi.org\/10.3389\/fcvm.2024.1420067.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3731_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s13023-025-03922-x","volume":"20","author":"RJ Hopkin","year":"2025","unstructured":"Hopkin RJ, Laney D, Kazemi S, Walter A. Fabry disease in females: organ involvement and clinical outcomes compared with the general population (103\/150 characters). Orphanet J Rare Dis. 2025;20(1):433. https:\/\/doi.org\/10.1186\/s13023-025-03922-x.","journal-title":"Orphanet J Rare Dis"},{"key":"3731_CR8","unstructured":"Human Gene Mutation Database (HGMD) Professional (released in 2021.2). https:\/\/portal.biobase-international.com\/hgmd\/pro\/start.php. Accessed 26 July 2025."},{"issue":"2","key":"3731_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbadis.2009.11.003","volume":"1802","author":"C Filoni","year":"2010","unstructured":"Filoni C, Caciotti A, Carraresi L, et al. Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta. 2010;1802(2):247\u201352. https:\/\/doi.org\/10.1016\/j.bbadis.2009.11.003.","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"3731_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/genes16091086","volume":"16","author":"DC Faro","year":"2025","unstructured":"Faro DC, Di Salvo S, Rodolico MS, Losi V, Capodanno D, Monte IP. Cardiac phenotypes in Fabry disease: genetic variability and clinical severity staging correlation in a reference center cohort. Genes (Basel). 2025;16(9):1086. https:\/\/doi.org\/10.3390\/genes16091086.","journal-title":"Genes (Basel)"},{"issue":"7","key":"3731_CR11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jfma.2023.10.004","volume":"123","author":"WL Hwu","year":"2024","unstructured":"Hwu WL. Deciphering the diagnostic dilemma: a comprehensive review of the Taiwanese cardiac variant in Fabry disease. J Formos Med Assoc. 2024;123(7):738\u201343. https:\/\/doi.org\/10.1016\/j.jfma.2023.10.004.","journal-title":"J Formos Med Assoc"},{"issue":"4","key":"3731_CR12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/jmg.28.4.232","volume":"28","author":"AJ Kirkilionis","year":"1991","unstructured":"Kirkilionis AJ, Riddell DC, Spence MW, Fenwick RG. Fabry disease in a large Nova Scotia kindred: carrier detection using leucocyte alpha-galactosidase activity and an NcoI polymorphism detected by an alpha-galactosidase cDNA clone. J Med Genet. 1991;28(4):232\u201340. https:\/\/doi.org\/10.1136\/jmg.28.4.232. (PMID:1677424;PMCID:PMC1016823).","journal-title":"J Med Genet"},{"issue":"2","key":"3731_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2019.103703","volume":"63","author":"JP Oliveira","year":"2020","unstructured":"Oliveira JP, Nowak A, Barbey F, et al. Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: natural history in males. Eur J Med Genet. 2020;63(2):103703. https:\/\/doi.org\/10.1016\/j.ejmg.2019.103703.","journal-title":"Eur J Med Genet"},{"key":"3731_CR14","first-page":"91","volume":"130","author":"P Rohman","year":"2015","unstructured":"Rohman P, Ramaswami U, Mehta A, Hughes DA. Three significant milestones and a review of the A143T mutation within one family with Anderson-Fabry disease. Nephron Clin Pract. 2015;130:91.","journal-title":"Nephron Clin Pract"},{"key":"3731_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000543920","volume":"28","author":"AM Paltzer","year":"2025","unstructured":"Paltzer AM, Quadri AM, Rasmussen C, Schiffmann R, Charrow J, Prada CE. Further clinical and biochemical phenotype of GLA p. A143T: a Fabry disease newborn screening experience. Nephron. 2025;28:1\u20137. https:\/\/doi.org\/10.1159\/000543920.","journal-title":"Nephron"},{"issue":"2","key":"3731_CR16","doi-asserted-by":"publisher","first-page":"108834","DOI":"10.1016\/j.ymgme.2024.108834","volume":"142","author":"A Lim","year":"2025","unstructured":"Lim A, Laney DA, Quintero D, Vuehrle A, Druss J, Wilcox WR. Further characterization of the GLA p.A143T phenotype through leveraging the genomic database, All of Us. Mol Genet Metab. 2025;142(2):108834. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108834.","journal-title":"Mol Genet Metab"},{"key":"3731_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.ejhg.5201184","volume":"12","author":"F Verovnik","year":"2004","unstructured":"Verovnik F, Benko D, Vujkovac B, et al. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet. 2004;12:678\u201381. https:\/\/doi.org\/10.1038\/sj.ejhg.5201184.","journal-title":"Eur J Hum Genet"},{"key":"3731_CR18","doi-asserted-by":"crossref","unstructured":"Beck M, Cox TM. Comment: Why are females with Fabry disease affected? Mol Genet Metab Rep. 2019;21:100529.","DOI":"10.1016\/j.ymgmr.2019.100529"},{"issue":"4","key":"3731_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/cge.14102","volume":"101","author":"DP Germain","year":"2022","unstructured":"Germain DP, Levade T, Hachulla E, et al. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022;101(4):390\u2013402. https:\/\/doi.org\/10.1111\/cge.14102.","journal-title":"Clin Genet"},{"issue":"5","key":"3731_CR20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341. https:\/\/doi.org\/10.1681\/ASN.2016090964.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3731_CR21","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","volume":"52","author":"BE Smid","year":"2015","unstructured":"Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015;52(4):262\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102872.","journal-title":"J Med Genet"},{"issue":"5","key":"3731_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2023.03.015","volume":"82","author":"M Santostefano","year":"2023","unstructured":"Santostefano M, Cappuccilli M, Gibertoni D, et al. Fabry disease nephropathy: histological changes with nonclassical mutations and genetic variants of unknown significance. Am J Kidney Dis. 2023;82(5):581-596.e0. https:\/\/doi.org\/10.1053\/j.ajkd.2023.03.015.","journal-title":"Am J Kidney Dis"},{"key":"3731_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545611","volume":"4","author":"R Mignani","year":"2025","unstructured":"Mignani R, Berti GM, Vischini G, et al. The Fabry nephropathy in patients with N215S variant. Nephron. 2025;4:1\u20135. https:\/\/doi.org\/10.1159\/000545611.","journal-title":"Nephron"},{"issue":"1","key":"3731_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bjophthalmol-2014-306433","volume":"100","author":"L van der Tol","year":"2016","unstructured":"van der Tol L, Sminia ML, Hollak CE, Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016;100(1):3\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306433.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"3731_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-017-0810-9","volume":"17","author":"HJ Lee","year":"2017","unstructured":"Lee HJ, Hsu TR, Hung SC, et al. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. BMC Neurol. 2017;17(1):25. https:\/\/doi.org\/10.1186\/s12883-017-0810-9.","journal-title":"BMC Neurol"},{"issue":"16","key":"3731_CR26","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/TCRM.S247814","volume":"22","author":"I Vardarli","year":"2020","unstructured":"Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and screening of patients with Fabry disease. Ther Clin Risk Manag. 2020;22(16):551\u20138. https:\/\/doi.org\/10.2147\/TCRM.S247814.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"3731_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109082","volume":"145","author":"Y Pan","year":"2025","unstructured":"Pan Y, Sniderman King L, Vengoechea E, et al. Enhancing Fabry disease screening and diagnostic efficiency: integration of enzyme, biomarker, and next-generation sequencing testing. Mol Genet Metab. 2025;145(1):109082. https:\/\/doi.org\/10.1016\/j.ymgme.2025.109082.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3731_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12882-017-0571-0.PMID:28499424;PMCID:PMC5427530","volume":"18","author":"PDM de Menezes Neves","year":"2017","unstructured":"de Menezes Neves PDM, Machado JR, Cust\u00f3dio FB, et al. Ultrastructural deposits appearing as \u201czebra bodies\u201d in renal biopsy: Fabry disease?- comparative case reports. BMC Nephrol. 2017;18(1):157. https:\/\/doi.org\/10.1186\/s12882-017-0571-0.PMID:28499424;PMCID:PMC5427530.","journal-title":"BMC Nephrol"},{"issue":"5","key":"3731_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, Peck DS, Atherton AM, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med. 2015;17(5):323\u201330. https:\/\/doi.org\/10.1038\/gim.2014.120.","journal-title":"Genet Med"},{"issue":"2","key":"3731_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijns9020031","volume":"9","author":"V Gragnaniello","year":"2023","unstructured":"Gragnaniello V, Burlina AP, Commone A, et al. Newborn screening for Fabry disease: current status of knowledge. Int J Neonatal Screen. 2023;9(2):31. https:\/\/doi.org\/10.3390\/ijns9020031.","journal-title":"Int J Neonatal Screen"},{"issue":"2","key":"3731_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101891","volume":"10","author":"DA Laney","year":"2024","unstructured":"Laney DA, Houde MF, Foley AL, et al. Prospective characterization of early symptom onset and progression in young pediatric patients with variants in the GLA gene across 5\u00a0years: longitudinal data from the Fabry MOPPet Study. Genet Med Open. 2024;10(2):101891. https:\/\/doi.org\/10.1016\/j.gimo.2024.101891.","journal-title":"Genet Med Open"},{"issue":"2","key":"3731_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.106967","volume":"138","author":"RJ Hopkin","year":"2023","unstructured":"Hopkin RJ, Cabrera GH, Jefferies JL, et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30\u00a0years of age: an analysis from the Fabry Registry. Mol Genet Metab. 2023;138(2):106967. https:\/\/doi.org\/10.1016\/j.ymgme.2022.106967.","journal-title":"Mol Genet Metab"},{"issue":"15","key":"3731_CR33","doi-asserted-by":"publisher","first-page":"1367252","DOI":"10.3389\/fimmu.2024.1367252","volume":"21","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Zhao Y, Li F, et al. Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy. Front Immunol. 2024;21(15):1367252. https:\/\/doi.org\/10.3389\/fimmu.2024.1367252.","journal-title":"Front Immunol"},{"issue":"8","key":"3731_CR34","doi-asserted-by":"publisher","first-page":"sfae194","DOI":"10.1093\/ckj\/sfae194","volume":"17","author":"JL Batista","year":"2024","unstructured":"Batista JL, Hariri A, Maski M, et al. Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry. Clin Kidney J. 2024;17(8):sfae194. https:\/\/doi.org\/10.1093\/ckj\/sfae194. (Erratum in: Clin Kidney J. 2024 Oct 17;17(10):sfae304. 10.1093\/ckj\/sfae304).","journal-title":"Clin Kidney J"},{"issue":"43","key":"3731_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2025.101215","volume":"11","author":"U Ramaswami","year":"2025","unstructured":"Ramaswami U, Pintos-Morell G, Kampmann C, et al. Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy. Mol Genet Metab Rep. 2025;11(43):101215. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101215.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"3731_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","volume":"130","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Kawashima S, Tozawa H, et al. Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: Phase\u00a0I and II\/III clinical studies. Mol Genet Metab. 2020;130(3):215\u201324. https:\/\/doi.org\/10.1016\/j.ymgme.2020.04.003.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3731_CR37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase\u00a01\/2 clinical trial. J Inherit Metab Dis. 2019;42(3):534\u201344. https:\/\/doi.org\/10.1002\/jimd.12080.","journal-title":"J Inherit Metab Dis"},{"key":"3731_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100968","volume":"25","author":"D Hughes","year":"2023","unstructured":"Hughes D, Gonzalez D, Maegawa G, et al. Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease. Genet Med. 2023;25:100968. https:\/\/doi.org\/10.1016\/j.gim.2023.100968.","journal-title":"Genet Med"},{"key":"3731_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52:353\u20138.","journal-title":"J Med Genet"},{"issue":"25","key":"3731_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100670","volume":"30","author":"RJ Hopkin","year":"2020","unstructured":"Hopkin RJ, Feldt-Rasmussen U, Germain DP, et al. Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: a Fabry Registry analysis stratified by phenotype. Mol Genet Metab Rep. 2020;30(25):100670. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100670.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"3731_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107780","volume":"141","author":"AP Burlina","year":"2024","unstructured":"Burlina AP, Politei J, Crespo A, et al. Stroke in patients with Fabry disease: a Fabry Registry analysis of natural history data from patients stratified by disease phenotype. Mol Genet Metab. 2024;141(2):107780. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107780.","journal-title":"Mol Genet Metab"},{"key":"3731_CR42","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2147\/DDDT.S249433","volume":"14","author":"R Parini","year":"2020","unstructured":"Parini R, Pintos-Morell G, Hennermann JB, et al. Analysis of renal and cardiac outcomes in male participants in the Fabry outcome survey starting agalsidase alfa enzyme replacement therapy before and after 18\u00a0years of age. Drug Des Devel Ther. 2020;14:2149\u201358. https:\/\/doi.org\/10.2147\/DDDT.S249433.","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"3731_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100530","volume":"19","author":"A Kritzer","year":"2019","unstructured":"Kritzer A, Siddharth A, Leestma K, Bodamer O. Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patients. Mol Genet Metab Rep. 2019;19(21):100530. https:\/\/doi.org\/10.1016\/j.ymgmr.2019.100530.","journal-title":"Mol Genet Metab Rep"},{"key":"3731_CR44","doi-asserted-by":"publisher","first-page":"106972","DOI":"10.1016\/j.ymgme.2022.107262","volume":"138","author":"FJ Perretta","year":"2023","unstructured":"Perretta FJ, Politei JM. Fabry disease: Lyso-GL3 normalization as a reachable therapeutic goal. Mol Genet Metab. 2023;138:106972.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3731_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12795","volume":"48","author":"M Holida","year":"2025","unstructured":"Holida M, Linhart A, Pisani A, et al. A phase\u00a0III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4\u2009weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2025;48(1):e12795. https:\/\/doi.org\/10.1002\/jimd.12795.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"3731_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.","journal-title":"J Med Genet"},{"issue":"7","key":"3731_CR47","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u00a0mg\/kg. PLoS One. 2007;2(7):e598. https:\/\/doi.org\/10.1371\/journal.pone.0000598.","journal-title":"PLoS One"},{"key":"3731_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","volume":"111","author":"SM Sirrs","year":"2014","unstructured":"Sirrs SM, Bichet DG, Casey R, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014;111:499\u2013506. https:\/\/doi.org\/10.1016\/j.ymgme.2014.01.014.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3731_CR49","doi-asserted-by":"publisher","first-page":"100805","DOI":"10.1016\/j.gimo.2023.100805","volume":"1","author":"E Riccio","year":"2023","unstructured":"Riccio E, Garofalo C, Capuano I, et al. New insights in efficacy of different ERT dosages in Fabry disease: switch and switch-back studies data following agalsidase beta shortage. Update of systematic review. Genet Med Open. 2023;1(1):100805. https:\/\/doi.org\/10.1016\/j.gimo.2023.100805.","journal-title":"Genet Med Open"},{"issue":"1","key":"3731_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24(1):137\u201348. https:\/\/doi.org\/10.1681\/ASN.2012030316.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3731_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/gim.2016.117","volume":"19","author":"A Pisani","year":"2017","unstructured":"Pisani A, Bruzzese D, Sabbatini M, Spinelli L, Imbriaco M, Riccio E. Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. Genet Med. 2017;19(3):275\u201382. https:\/\/doi.org\/10.1038\/gim.2016.117.","journal-title":"Genet Med"},{"issue":"6","key":"3731_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase\u00a0III BALANCE study. J Med Genet. 2024;61(6):520\u201330. https:\/\/doi.org\/10.1136\/jmg-2023-109445.","journal-title":"J Med Genet"},{"issue":"1","key":"3731_CR53","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase\u00a03 open-label study. Orphanet J Rare Dis. 2023;18(1):332. https:\/\/doi.org\/10.1186\/s13023-023-02937-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3731_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12325-024-03062-x","volume":"42","author":"K Azimpour","year":"2025","unstructured":"Azimpour K, Tordoff-Gibson C, Dorling P, et al. Influence of treatment effect modifiers in Fabry disease: a systematic literature review. Adv Ther. 2025;42(2):579\u201396. https:\/\/doi.org\/10.1007\/s12325-024-03062-x.","journal-title":"Adv Ther"},{"key":"3731_CR55","unstructured":"Fabrazyme [US Food and Drug Administration package insert]. Cambridge: Genzyme Corporation;2024."},{"key":"3731_CR56","unstructured":"Replagal [EMA package insert]: Dublin: Takeda Pharmaceutical International AG Ireland Branch;2022"},{"key":"3731_CR57","unstructured":"Elfabrio [US Food and Drug Administration package insert].Parma: Chiesi Farmaceutici S.p.A.;2023."},{"issue":"4","key":"3731_CR58","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40259-025-00723-3","volume":"39","author":"M Lenders","year":"2025","unstructured":"Lenders M, Menke ER, Brand E. Progress and challenges in the treatment of Fabry disease. BioDrugs. 2025;39(4):517\u201335. https:\/\/doi.org\/10.1007\/s40259-025-00723-3.","journal-title":"BioDrugs"},{"key":"3731_CR59","doi-asserted-by":"crossref","unstructured":"Riedy M, Zheng N, Tuttle K. P055: Successful utilization of immune tolerance induction in a pediatric patient with classic Fabry disease: a case report. Genet Med Open. 2026;4(Suppl 1):103546.","DOI":"10.1016\/j.gimo.2026.103546"},{"key":"3731_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03131-y","volume":"19","author":"A Jovanovic","year":"2024","unstructured":"Jovanovic A, Miller-Hodges E, Castriota F, et al. A systematic literature review on the health-related quality of life and economic burden of Fabry disease. Orphanet J Rare Dis. 2024;19:181. https:\/\/doi.org\/10.1186\/s13023-024-03131-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3731_CR61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1510198.","journal-title":"N Engl J Med"},{"issue":"4","key":"3731_CR62","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase\u00a0III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"issue":"1-2","key":"3731_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase\u00a03 ATTRACT study. Mol Genet Metab. 2020;131(1\u20132):219\u201328. https:\/\/doi.org\/10.1016\/j.ymgme.2020.07.007.","journal-title":"Mol Genet Metab"},{"key":"3731_CR64","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jmg-2022-108669","volume":"60","author":"DA Hughes","year":"2023","unstructured":"Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet. 2023;60:722\u201331.","journal-title":"J Med Genet"},{"issue":"1","key":"3731_CR65","doi-asserted-by":"publisher","first-page":"e12771","DOI":"10.1002\/jimd.12771","volume":"48","author":"DA Hughes","year":"2025","unstructured":"Hughes DA, Sunder-Plassmann G, Jovanovic A, et al. Renal and multisystem effectiveness of 39\u00a0years of migalastat in a global real-world cohort: results from the followME Fabry Pathfinders registry. J Inherit Metab Dis. 2025;48(1):e12771.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3731_CR66","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-025-03600-y","volume":"20","author":"M Lenders","year":"2025","unstructured":"Lenders M, Nowak A, Cybulla M, et al. Impact of enzyme replacement therapy and migalastat on disease progression in females with Fabry disease. Orphanet J Rare Dis. 2025;20(1):79. https:\/\/doi.org\/10.1186\/s13023-025-03600-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3731_CR67","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/jimd.12773","volume":"47","author":"A Pisani","year":"2024","unstructured":"Pisani A, Wilson KM, Batista JL, et al. Clinical outcomes in patients switching from agalsidase beta to migalastat: a Fabry Registry analysis. J Inherit Metab Dis. 2024;47(5):1080\u201395. https:\/\/doi.org\/10.1002\/jimd.12773.","journal-title":"J Inherit Metab Dis"},{"key":"3731_CR68","unstructured":"Galafold [US Food and Drug Administration package insert]. Cranbury, NJ: Amicus Therapeutics, revised August 2018 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208623lbl.pdf"},{"key":"3731_CR69","unstructured":"Mehta A, Hughes DA. Fabry Disease. 2002 Aug 5 [Updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/."},{"issue":"2","key":"3731_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108741","volume":"144","author":"S Gosling","year":"2025","unstructured":"Gosling S, Kilbride C, Mansfield L, Hughes D, Bailey D. Co-design of a physical activity and sedentary behavior intervention for adults with Fabry disease. Mol Genet Metab. 2025;144(2):108741. https:\/\/doi.org\/10.1016\/j.ymgme.2024.108741.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"3731_CR71","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/jpm13060904","volume":"13","author":"G Gambini","year":"2023","unstructured":"Gambini G, Scartozzi L, Giannuzzi F, et al. Ophthalmic manifestations in Fabry disease: updated review. J Pers Med. 2023;13(6):904. https:\/\/doi.org\/10.3390\/jpm13060904.","journal-title":"J Pers Med"},{"issue":"8","key":"3731_CR72","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/OPTH.S66748","volume":"19","author":"PG Davey","year":"2014","unstructured":"Davey PG. Fabry disease: a survey of visual and ocular symptoms. Clin Ophthalmol. 2014;19(8):1555\u201360. https:\/\/doi.org\/10.2147\/OPTH.S66748.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"3731_CR73","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1179\/1754762811Y0000000004","volume":"12","author":"DJ Clinkard","year":"2011","unstructured":"Clinkard DJ, Amoodi H, Lin VY, Chen JM, Nedzelski JM. Improved hearing with cochlear implantation in Fabry\u2019s disease. Cochlear Implants Int. 2011;12(4):238\u201340. https:\/\/doi.org\/10.1179\/1754762811Y0000000004.","journal-title":"Cochlear Implants Int"},{"key":"3731_CR74","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","volume":"52","author":"DG Warnock","year":"2015","unstructured":"Warnock DG, Thomas CP, Vujkovac B, et al. Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet. 2015;52:860\u20136.","journal-title":"J Med Genet"},{"issue":"3","key":"3731_CR75","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40620-023-01853-z","volume":"37","author":"B Yu","year":"2024","unstructured":"Yu B, Atta MG, Brennan DC, Kant S. Outcomes and management of kidney transplant recipients with Fabry disease: a review. J Nephrol. 2024;37(3):561\u201371. https:\/\/doi.org\/10.1007\/s40620-023-01853-z.","journal-title":"J Nephrol"},{"issue":"6","key":"3731_CR76","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/medicina56060284","volume":"56","author":"I Capelli","year":"2020","unstructured":"Capelli I, Aiello V, Gasperoni L, et al. Kidney transplant in Fabry disease: a revision of the literature. Medicina (Kaunas). 2020;56(6):284. https:\/\/doi.org\/10.3390\/medicina56060284.","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"3731_CR77","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/biomedicines13030624","volume":"13","author":"SE Thompson","year":"2025","unstructured":"Thompson SE, Roy A, Geberhiwot T, Gehmlich K, Steeds RP. Fabry disease: insights into pathophysiology and novel therapeutic strategies. Biomedicines. 2025;13(3):624. https:\/\/doi.org\/10.3390\/biomedicines13030624.","journal-title":"Biomedicines"},{"issue":"14","key":"3731_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10143026","volume":"10","author":"I Vardarli","year":"2021","unstructured":"Vardarli I, Weber M, Rischpler C, F\u00fchrer D, Herrmann K, Weidemann F. Fabry cardiomyopathy: current treatment and future options. J Clin Med. 2021;10(14):3026. https:\/\/doi.org\/10.3390\/jcm10143026.","journal-title":"J Clin Med"},{"issue":"26","key":"3731_CR79","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.945873","volume":"17","author":"K Muras-Szwedziak","year":"2025","unstructured":"Muras-Szwedziak K, W\u00f3jcik M, Wojtyczka O, Kaczmarek K. Enzyme replacement and immunosuppression in heart transplant recipients with Fabry cardiomyopathy: a 7-year case study. Am J Case Rep. 2025;17(26):e945873. https:\/\/doi.org\/10.12659\/AJCR.945873.","journal-title":"Am J Case Rep"},{"issue":"16","key":"3731_CR80","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","volume":"24","author":"Y Schuller","year":"2016","unstructured":"Schuller Y, Linthorst GE, Hollak CE, Van Schaik IN, Biegstraaten M. Pain management strategies for neuropathic pain in Fabry disease\u2013a systematic review. BMC Neurol. 2016;24(16):25. https:\/\/doi.org\/10.1186\/s12883-016-0549-8. (Erratum. In: BMC Neurol. 2016. 16:67. 10.1186\/s12883-016-0590-7).","journal-title":"BMC Neurol"},{"issue":"1","key":"3731_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02796-1","volume":"18","author":"KM Stepien","year":"2023","unstructured":"Stepien KM, Broomfield A, Cole D, et al. Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel. Orphanet J Rare Dis. 2023;18(1):203. https:\/\/doi.org\/10.1186\/s13023-023-02796-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"3731_CR82","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/cns.12542","volume":"22","author":"JM Politei","year":"2016","unstructured":"Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther. 2016;22(7):568\u201376. https:\/\/doi.org\/10.1111\/cns.12542.","journal-title":"CNS Neurosci Ther"},{"issue":"18","key":"3731_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184168","volume":"10","author":"JN Rajan","year":"2021","unstructured":"Rajan JN, Ireland K, Johnson R, Stepien KM. Review of mechanisms, pharmacological management, psychosocial implications, and holistic treatment of pain in Fabry disease. J Clin Med. 2021;10(18):4168. https:\/\/doi.org\/10.3390\/jcm10184168.","journal-title":"J Clin Med"},{"issue":"2","key":"3731_CR84","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/biomedicines13020249","volume":"13","author":"AB Johansen","year":"2025","unstructured":"Johansen AB, Feldt-Rasmussen U, Klokker M. Dizziness in Fabry disease. Biomedicines. 2025;13(2):249. https:\/\/doi.org\/10.3390\/biomedicines13020249.","journal-title":"Biomedicines"},{"issue":"2","key":"3731_CR85","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","volume":"37","author":"FE Bolsover","year":"2014","unstructured":"Bolsover FE, Murphy E, Cipolotti L, Werring DJ, Lachmann RH. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014;37(2):177\u201387. https:\/\/doi.org\/10.1007\/s10545-013-9643-x.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"3731_CR86","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13023-020-1307-y","volume":"15","author":"S K\u00f6rver","year":"2020","unstructured":"K\u00f6rver S, Geurtsen GJ, Hollak CEM, et al. Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain. Orphanet J Rare Dis. 2020;15(1):28. https:\/\/doi.org\/10.1186\/s13023-020-1307-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"3731_CR87","doi-asserted-by":"publisher","first-page":"1217618","DOI":"10.3389\/fneur.2023.1217618","volume":"5","author":"B Blaszczyk","year":"2023","unstructured":"Blaszczyk B, Wieckiewicz M, Kusztal M, et al. Fabry disease and sleep disorders: a systematic review. Front Neurol. 2023;5(14):1217618. https:\/\/doi.org\/10.3389\/fneur.2023.1217618.","journal-title":"Front Neurol"},{"issue":"3","key":"3731_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/nu15030658","volume":"15","author":"G Gugelmo","year":"2023","unstructured":"Gugelmo G, Vitturi N, Francini-Pesenti F, et al. Gastrointestinal manifestations and low-FODMAP protocol in a cohort of Fabry disease adult patients. Nutrients. 2023;15(3):658. https:\/\/doi.org\/10.3390\/nu15030658.","journal-title":"Nutrients"},{"issue":"4","key":"3731_CR89","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1756283X16642936","volume":"9","author":"C Zar-Kessler","year":"2016","unstructured":"Zar-Kessler C, Karaa A, Sims KB, Clarke V, Kuo B. Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis. Therap Adv Gastroenterol. 2016;9(4):626\u201334. https:\/\/doi.org\/10.1177\/1756283X16642936.","journal-title":"Therap Adv Gastroenterol"},{"key":"3731_CR90","volume":"41","author":"V Berstein","year":"2024","unstructured":"Berstein V, Pirotzky EM, Taconelli HD, et al. Comparative pharmacokinetics and pharmacodynamics of two formulations of agalsidase beta (agalsidase Biosidus) and Fabrazyme\u00ae by intravenous infusion in healthy male volunteers. Mol Genet Metab Rep. 2024;41:101149.","journal-title":"Mol Genet Metab Rep"},{"key":"3731_CR91","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). A proof-of Concept Study to Assess Safety and Tolerability of HM15421\/\u200bGC1134A in Patients With Fabry Disease. Posted March 3, 2025. Updated July 23, 2025. Accessed 26 July 2025."},{"key":"3731_CR92","doi-asserted-by":"publisher","unstructured":"Banikazemi M, Goker-Alpan O, Nedd KJ, et al. A phase\u00a04 study to evaluate the safety and tolerability of higher infusion rates of agalsidase beta to shorten infusion duration in Fabry disease: interim analysis: SA-PO655. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.20249th2t8ga.","DOI":"10.1681\/ASN.20249th2t8ga"},{"issue":"1","key":"3731_CR93","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000546152","volume":"50","author":"F Perretta","year":"2025","unstructured":"Perretta F, Cabrera G, Politei J. New drugs available for Fabry disease. Kidney Blood Press Res. 2025;50(1):366\u201374. https:\/\/doi.org\/10.1159\/000546152.","journal-title":"Kidney Blood Press Res"},{"issue":"19","key":"3731_CR94","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","volume":"27","author":"RWD Welford","year":"2018","unstructured":"Welford RWD, M\u00fchlemann A, Garzotti M, et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet. 2018;27(19):3392\u2013403. https:\/\/doi.org\/10.1093\/hmg\/ddy248.","journal-title":"Hum Mol Genet"},{"key":"3731_CR95","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024nerf8g2h","author":"E Wallace","year":"2024","unstructured":"Wallace E, Germain DP, Hughes D, et al. Lucerastat effect on kidney function in patients with Fabry disease: results from the phase\u00a03 clinical program SA-PO654. J Am Soc Nephrol. 2024. https:\/\/doi.org\/10.1681\/ASN.2024nerf8g2h.","journal-title":"J Am Soc Nephrol"},{"key":"3731_CR96","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). Study of the safety and biologic activity of AL01211 in treatment naive males with classic Fabry disease. ClinicalTrials.gov. November 2, 2023. Updated July 30, 2024. Accessed 26 July 2025."},{"issue":"2","key":"3731_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.11.002","volume":"138","author":"PB Deegan","year":"2023","unstructured":"Deegan PB, Goker-Alpan O, Geberhiwot T, et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3\u00a0years in adult males with classic Fabry disease in an open-label phase\u00a02 study and its extension study. Mol Genet Metab. 2023;138(2):106963. https:\/\/doi.org\/10.1016\/j.ymgme.2022.11.002.","journal-title":"Mol Genet Metab"},{"key":"3731_CR98","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants \u226516\u00a0years of age with Fabry disease (PERIDOT). ClinicalTrials.gov. January 25, 2022. Updated January 23, 2025. Accessed 26 July 2025."},{"key":"3731_CR99","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease (CARAT). ClinicalTrials.gov. March 15, 2022. Updated January 13, 2025. Accessed 26 July, 2025."},{"key":"3731_CR100","unstructured":"Sanofi, Press Release: Sanofi\u2019s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease, press release 2\/2\/2026 https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2026\/2026-02-02-06-00-00-3229947. Accessed 26 July 2025."},{"issue":"1","key":"3731_CR101","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2119\/molmed.2015.00088","volume":"21","author":"KM Ashe","year":"2015","unstructured":"Ashe KM, Budman E, Bangari DS, et al. Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med. 2015;21(1):389\u201399. https:\/\/doi.org\/10.2119\/molmed.2015.00088.","journal-title":"Mol Med"},{"issue":"4","key":"3731_CR102","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/imj.16603","volume":"55","author":"A Tsatsaronis","year":"2025","unstructured":"Tsatsaronis A, Tiong M, Nicholls K, Ruderman I. Sodium-glucose cotransporter\u00a02 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series. Intern Med J. 2025;55(4):617\u201321. https:\/\/doi.org\/10.1111\/imj.16603.","journal-title":"Intern Med J"},{"issue":"43","key":"3731_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2025.101229","volume":"14","author":"EP McCarron","year":"2025","unstructured":"McCarron EP, Chinnadurai R, Meyer J, et al. Real-world clinical outcomes in adult patients with Fabry disease: a 20-year retrospective observational cohort study from a single centre. Mol Genet Metab Rep. 2025;14(43):101229. https:\/\/doi.org\/10.1016\/j.ymgmr.2025.101229.","journal-title":"Mol Genet Metab Rep"},{"issue":"9","key":"3731_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.924710","volume":"8","author":"G Bertoldi","year":"2022","unstructured":"Bertoldi G, Carraro G, Ravarotto V, et al. The effect of green tea as an adjuvant to enzyme replacement therapy on oxidative stress in Fabry disease: a pilot study. Front Nutr. 2022;8(9):924710. https:\/\/doi.org\/10.3389\/fnut.2022.924710.","journal-title":"Front Nutr"},{"key":"3731_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.110664","volume":"72","author":"F Francini-Pesenti","year":"2020","unstructured":"Francini-Pesenti F, Ravarotto V, Bertoldi G, Spinella P, Cal\u00f2 LA. Could nutritional therapy take us further in our approaches to Fabry disease? Nutrition. 2020;72:110664. https:\/\/doi.org\/10.1016\/j.nut.2019.110664.","journal-title":"Nutrition"},{"issue":"1","key":"3731_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70073","volume":"15","author":"A Khan","year":"2025","unstructured":"Khan A, Barber DL, McKillop WM, et al. Lentivirus-mediated gene therapy for Fabry disease: 5-year end-of-study results from the Canadian FACTs trial. Clin Transl Med. 2025;15(1):e70073. https:\/\/doi.org\/10.1002\/ctm2.70073.","journal-title":"Clin Transl Med"},{"issue":"10","key":"3731_CR107","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1200\/JCO-25-01844","volume":"44","author":"DJ Benedetti","year":"2026","unstructured":"Benedetti DJ, Marron JM, Kodish E. Gene therapy-related malignancy and the risk of cancer exceptionalism. J Clin Oncol. 2026;44(10):835\u20139. https:\/\/doi.org\/10.1200\/JCO-25-01844.","journal-title":"J Clin Oncol"},{"key":"3731_CR108","unstructured":"Wexler M., Avrobio Stopping Its Gene Therapy Program for Fabry Disease, Fabry Disease News, January 14, 2022. https:\/\/fabrydiseasenews.com\/2022\/01\/14\/avrobio-stopping-gene-therapy-avr-rd-01-program-clinical-trial-fabry-patients\/. Accessed 26 July 2025."},{"key":"3731_CR109","unstructured":"Glafabra website, https:\/\/www.glafabra.com\/. Accessed 22 Apr 2026."},{"key":"3731_CR110","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease, Clinicaltrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03454893. Accessed 26 July 2025."},{"key":"3731_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107884","author":"RJ Hopkin","year":"2024","unstructured":"Hopkin RJ, Ganesh J, Bernat J, et al. Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease: updated results from an ongoing phase\u00a01\/2 study (STAAR). Mol Genet Metab. 2024. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107884.","journal-title":"Mol Genet Metab"},{"key":"3731_CR112","unstructured":"Sangamo, Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease. May\u00a06, 2025. https:\/\/investor.sangamo.com\/news-releases\/news-release-details\/sangamo-therapeutics-announces-important-derisking-milestones. Accessed 26 July 2025."},{"key":"3731_CR113","unstructured":"Sangamo, Press release dated 12\/18\/2025, Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease https:\/\/investor.sangamo.com\/news-releases\/news-release-details\/sangamo-therapeutics-initiates-rolling-submission-bla-us-fda-st. Accessed 9 Jan 2026."},{"key":"3731_CR114","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). Safety, PK\/\u200bPD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease ClinicalTrials.gov. February 21, 2024. Updated April 11, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06270316. Accessed 26 July 2025."},{"key":"3731_CR115","unstructured":"Uniqure, Press release dated 9\/5\/2025, \u201cuniQure Announces Initial AMT-191 Phase\u00a0I\/IIa Data Showing Sustained Increases in \u03b1-Gal A Enzyme Activity in Patients with Fabry Disease\u201d https:\/\/uniqure.gcs-web.com\/news-releases\/news-release-details\/uniqure-announces-initial-amt-191-phase-iiia-data-showing . Accessed 9 Jan 2026."},{"issue":"6","key":"3731_CR116","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","volume":"30","author":"JM Jeyakumar","year":"2023","unstructured":"Jeyakumar JM, Kia A, Tam LCS, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30(6):487\u2013502. https:\/\/doi.org\/10.1038\/s41434-022-00381-y.","journal-title":"Gene Ther"},{"issue":"2","key":"3731_CR117","first-page":"S77","volume":"129","author":"D Hughes","year":"2020","unstructured":"Hughes D, Goker-Alpan O, Ganesh J, et al. A phase\u00a0I\/II multicenter gene therapy clinical study for Fabry disease. Mol Genet Metab. 2020;129(2):S77.","journal-title":"Mol Genet Metab"},{"key":"3731_CR118","unstructured":"Wexler, M. Freeline pauses development of Fabry disease gene therapy FLT190, Fabry Disease News, April 14, 2023. https:\/\/fabrydiseasenews.com\/news\/development-fabry-disease-gene-therapy-flt190-paused\/. Accessed 26 July 2025."},{"key":"3731_CR119","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). An Open-label, Phase\u00a01\/\u200b2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease ClinicalTrials.gov. August 20, 2020. Updated April 8, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04519749. Accessed 26 July 2025."},{"key":"3731_CR120","unstructured":"4DMT Presents Interim Data from 4D-310 INGLAXA Phase\u00a01\/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium\u2122 2024, February 12, 2024. https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-presents-interim-data-4d-310-inglaxa-phase-12-clinical. Accessed 26 July 2025."},{"key":"3731_CR121","unstructured":"4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway, January 10, 2025. https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-focuses-pipeline-prioritize-4d-150-wet-amd-dme-and-4d-710. Accessed 26 July 2025."},{"issue":"23","key":"3731_CR122","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.3390\/jcm13237195","volume":"13","author":"MC Carella","year":"2024","unstructured":"Carella MC, Forleo C, Caretto P, et al. Overcoming resistance in Anderson-Fabry disease: current therapeutic challenges and future perspectives. J Clin Med. 2024;13(23):7195. https:\/\/doi.org\/10.3390\/jcm13237195.","journal-title":"J Clin Med"},{"key":"3731_CR123","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251378455","volume":"31","author":"X Pang","year":"2025","unstructured":"Pang X, Fu J, Zhou Z, et al. Recent advances in gene therapy for hemophilia. Clin Appl Thromb Hemost. 2025;31:10760296251378455. https:\/\/doi.org\/10.1177\/10760296251378455.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"3731_CR124","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, Yin L, Theisen M, et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am J Hum Genet. 2019;104(4):625\u201337. https:\/\/doi.org\/10.1016\/j.ajhg.2019.02.003.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"3731_CR125","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ajhg.2023.07.013","volume":"110","author":"M Ter Huurne","year":"2023","unstructured":"Ter Huurne M, Parker BL, Liu NQ, et al. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals. Am J Hum Genet. 2023;110(9):1600\u20135. https:\/\/doi.org\/10.1016\/j.ajhg.2023.07.013.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"3731_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12058","volume":"10","author":"J Seras-Franzoso","year":"2021","unstructured":"Seras-Franzoso J, D\u00edaz-Riascos ZV, Corchero JL, et al. Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders. J Extracell Vesicles. 2021;10(5):e12058. https:\/\/doi.org\/10.1002\/jev2.12058.","journal-title":"J Extracell Vesicles"},{"key":"3731_CR127","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.). A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants. April 1, 2025. Updated July 3, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06904261. Accessed 26 July 2025."},{"key":"3731_CR128","unstructured":"ClinicalTrials.gov. National Library of Medicine (U.S.) A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease (FLY) March 18, 2024. Updated December 20, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06328608. Accessed 26 July 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03731-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03731-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03731-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:37Z","timestamp":1794254617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03731-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":128,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3731"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03731-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dawn A. Laney is a member of the North American Fabry Registry Board, consults and\/or has been an investigator and\/or coordinator in clinical trials sponsored by Amicus Therapeutics, Chiesi Farmaceutici, Sangamo, Sanofi-Genzyme, and Takeda-Shire. These activities have been monitored and found to be in compliance with the conflict-of-interest policies at the Emory University School of Medicine. Suma P. Shankar is Albert Rowe endowed chair in Genetics and receives salary and research support. The authors report no other conflicts of interest in this work. Madelena M. Martin has nothing to disclose. Ayaka Suzuki has nothing to disclose. Siddarth V. Shankar has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}